Silence Therapeutics PLC Silence Therapeutics to Participate in Conferences (5527T)
July 21 2020 - 1:00AM
UK Regulatory
TIDMSLN
RNS Number : 5527T
Silence Therapeutics PLC
21 July 2020
Silence Therapeutics to Participate in US Virtual Investor
Conferences in August
21 July 2020
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the
Company"), a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases, today
announces that Company management will be participating in three
virtual conferences, details of which can be found below:
William Blair Biotech Focus Conference
Date: Thursday, August 6, 2020
Time: 2:00 pm EDT (19:00 BST)
Panel: 30 Years of RNA-Targeted Therapies - Where Are
We Now
BTIG Virtual Biotechnology Conference
Date: Monday, August 10, 2020
Time: 9:30 am EDT (14:30 BST)
Webcast link: Silence Therapeutics fireside chat
Canaccord 40(th) Annual Growth Conference
Date: Thursday, August 13, 2020
Time: 11:30 am EDT (16:30 BST)
Webcast link: Silence Therapeutics presentation
Live webcasts of the BTIG Virtual Biotechnology Conference and
the Canaccord Growth Conference can be accessed via the Investors
section of the Company's website at www.silence-therapeutics.com .
An archived replay of the webcasts will be available for 60 days on
the Company's website after the conference.
For more information, please contact:
Silence Therapeutics plc Tel: +44 (0)20 3457
Iain Ross, Executive Chairman 6900
Rob Quinn, Chief Financial Officer
Investec (Nominated Adviser and Broker) Tel: +44 (0) 20
Daniel Adams/Gary Clarence 7597 5970
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
U.S. IR Tel: +1 (443) 213-0505
Westwicke
Peter Vozzo
peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Its proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-associated proteins. Silence's proprietary
RNA chemistries and delivery systems are designed to improve the
stability of molecules and enhance effective delivery to target
cells, providing a powerful modular technology well suited to
tackle life-threatening diseases. The Company has secured high
value research and collaboration agreements with AstraZeneca,
Mallinckrodt Pharmaceuticals and Takeda. For more information,
please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCRMMBTMTJTTFM
(END) Dow Jones Newswires
July 21, 2020 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024